WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Ceribell clears three EEG algorithms under K261712 with no age limit Oura shelves its $2.2B Nasdaq IPO four weeks after filing VCD Medical clears VEnice, a clip that closes varicose veins without heat Sofinnova closes an 82 million euro fund to start six to eight device companies Nyxoah hires former Teleflex CEO Liam Kelly to run the Genio US launch SI-BONE clears Granite Onyx, its first compromised bone implant outside the pelvis Route 92 Medical clears the FreeClimb 46, the smallest catheter in its stroke line Insera clears the CLEAR aspiration system for peripheral clot removal under K253404 Webster Equity takes Lifecore Biomedical private at $6.28 a share plus CVRs Ceribell clears three EEG algorithms under K261712 with no age limit Oura shelves its $2.2B Nasdaq IPO four weeks after filing VCD Medical clears VEnice, a clip that closes varicose veins without heat Sofinnova closes an 82 million euro fund to start six to eight device companies Nyxoah hires former Teleflex CEO Liam Kelly to run the Genio US launch SI-BONE clears Granite Onyx, its first compromised bone implant outside the pelvis Route 92 Medical clears the FreeClimb 46, the smallest catheter in its stroke line Insera clears the CLEAR aspiration system for peripheral clot removal under K253404 Webster Equity takes Lifecore Biomedical private at $6.28 a share plus CVRs

Leadership

Nyxoah hires former Teleflex CEO Liam Kelly to run the Genio US launch

MedDevice Startups Staff · 22 hrs ago · 2 min read · Via MassDevice

Nyxoah named Liam Kelly chief executive on September 29, effective October 1. Kelly ran Teleflex. He replaces Olivier Taelman, who led the Belgian neuromodulation company for seven years.

Nyxoah's Genio hypoglossal nerve stimulator won FDA approval in mid-2025 and sells against Inspire Medical. Genio carries no lead and no implanted battery, taking power wirelessly through the skin from a worn unit. The company raised $95 million in a summer offering to fund the US build-out.

Trading a Europe-based, approval-era CEO for a US large-cap operator is the move a device company makes when the constraint shifts from the submission to the sales force. Board chair Robert Taub cited Kelly's record scaling organizations and driving commercial performance.

Questions & Answers

Who is the new CEO of Nyxoah?

Nyxoah named Liam Kelly, former chief executive of Teleflex, as its CEO on September 29, 2026, effective October 1. He succeeds Olivier Taelman.

What is the Nyxoah Genio device?

Genio is Nyxoah's implantable hypoglossal nerve stimulator for obstructive sleep apnea. It has no lead and no implanted battery, drawing power wirelessly through the skin from a worn unit, and won FDA approval in mid-2025.

How much has Nyxoah raised for its US launch?

Nyxoah raised $95 million in a public offering during the summer of 2026 to expand its US commercial operations for Genio.

← Back to Startups